TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06911333: A Phase I/IIa Trial of AD1208, a Cell Cycle Inhibitor/MASTL Inhibitor, as a Single Agent or a Combination in Subjects With Any Progressive, Locally Advanced(Unresectable) or Metastatic Solid Tumors

Sponsor: Avelos Therapeutics Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$1,924,230

Rescue Site Savings

+$1,256,640

Unlock Full NCT06911333 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06911333 Rescue Dossier →